CONVENIENTLY IMPLANTABLE SUSTAINED RELEASE DRUG COMPOSITIONS
First Claim
Patent Images
1. A method of delivering the sustained release of an active agent to the eye of a subject comprising:
- injecting into the eye of a subject in need of such treatment a therapeutically effective amount of at least one pharmaceutically active agent, or acceptable salt thereof, in a liquid pharmaceutical composition consisting essentially of at least one excipient selected from the group consisting of the mono, di, and tri esters of O-acetylcitric acid or O-propionylcitric acid or O-butyrylcitric acid with C1 to C10 straight and branched chain aliphatic alcohols;
the mono, di, and tri esters of citric acid with C1 to C10 straight and branched chain aliphatic alcohols, wherein the amount of the excipient is sufficient to evenly dissolve or disperse the entire amount of the active agent in the composition;
wherein upon initial injection into the eye the composition maintains its integrity as a single bolus; and
wherein said excipient releases the active agent from the composition for a continuous and sustained period of at least about five days.
0 Assignments
0 Petitions
Accused Products
Abstract
This invention provides for biocompatible and biodegradable syringeable liquid, implantable solid, and injectable gel pharmaceutical formulations useful for the treatment of systemic and local disease states.
-
Citations
10 Claims
-
1. A method of delivering the sustained release of an active agent to the eye of a subject comprising:
-
injecting into the eye of a subject in need of such treatment a therapeutically effective amount of at least one pharmaceutically active agent, or acceptable salt thereof, in a liquid pharmaceutical composition consisting essentially of at least one excipient selected from the group consisting of the mono, di, and tri esters of O-acetylcitric acid or O-propionylcitric acid or O-butyrylcitric acid with C1 to C10 straight and branched chain aliphatic alcohols;
the mono, di, and tri esters of citric acid with C1 to C10 straight and branched chain aliphatic alcohols, wherein the amount of the excipient is sufficient to evenly dissolve or disperse the entire amount of the active agent in the composition;wherein upon initial injection into the eye the composition maintains its integrity as a single bolus; and wherein said excipient releases the active agent from the composition for a continuous and sustained period of at least about five days. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
-
Specification